588 related articles for article (PubMed ID: 8670328)
1. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
2. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
4. Urinary C3d is elevated in patients with active Lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up.
Ganguly S; Majumder S; Kumar S; Gupta R; Muhammed H; Shobha V; Aggarwal A; Misra R
Lupus; 2020 Nov; 29(13):1800-1806. PubMed ID: 32807020
[TBL] [Abstract][Full Text] [Related]
5. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis.
Song D; Guo WY; Wang FM; Li YZ; Song Y; Yu F; Zhao MH
Am J Med Sci; 2017 Mar; 353(3):247-257. PubMed ID: 28262211
[TBL] [Abstract][Full Text] [Related]
6. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
Buyon JP; Tamerius J; Belmont HM; Abramson SB
Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018
[TBL] [Abstract][Full Text] [Related]
7. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
8. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.
Julkunen H; Ekblom-Kullberg S; Miettinen A
Rheumatol Int; 2012 Aug; 32(8):2445-51. PubMed ID: 21706294
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
10. Complement activation in patients with systemic lupus erythematosus without nephritis.
Mollnes TE; Haga HJ; Brun JG; Nielsen EW; Sjöholm A; Sturfeldt G; Mårtensson U; Bergh K; Rekvig OP
Rheumatology (Oxford); 1999 Oct; 38(10):933-40. PubMed ID: 10534542
[TBL] [Abstract][Full Text] [Related]
11. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
Ho A; Barr SG; Magder LS; Petri M
Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
[TBL] [Abstract][Full Text] [Related]
12. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
Röther E; Lang B; Coldewey R; Hartung K; Peter HH
Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
[TBL] [Abstract][Full Text] [Related]
13. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
Kerr LD; Adelsberg BR; Schulman P; Spiera H
Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
[TBL] [Abstract][Full Text] [Related]
14. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
[TBL] [Abstract][Full Text] [Related]
15. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
16. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
17. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
Lood C; Eriksson S; Gullstrand B; Jönsen A; Sturfelt G; Truedsson L; Bengtsson AA
Lupus; 2012 Nov; 21(13):1423-32. PubMed ID: 22878256
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
19. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome.
Hammond A; Rudge AC; Loizou S; Bowcock SJ; Walport MJ
Arthritis Rheum; 1989 Mar; 32(3):259-64. PubMed ID: 2522783
[TBL] [Abstract][Full Text] [Related]
20. Glomerular c4d staining can be an indicator of disease activity in lupus nephritis.
Sahin OZ; Gurses S; Taslı F; Yavas H; Ersoy R; Uzum A; Cirit M
Ren Fail; 2013; 35(2):222-5. PubMed ID: 23176021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]